)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Hamlet BioPharma
Hamlet BioPharma (HAMLET) investor relations material
Hamlet BioPharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary13 Nov, 2026
Executive summary
Phase III clinical treatment of patients with non-muscle invasive bladder cancer began in September at Motol Hospital in Prague; Alpha1H was produced to Phase III quality and shipped to the site.
Development advanced across cancer and anti-infectives; three Phase II studies have been completed on a reported budget of less than SEK 300 million.
Commercialization discussions for Alpha1H in bladder cancer continued with a leading German pharmaceutical company, with potential co-development and market access dependent on Phase III results and approval.
Financial highlights
Q1 net sales were KSEK 0 versus KSEK 0 YoY; other operating income was KSEK 2 versus KSEK 0.
EBITDA was KSEK -8,994 versus -9,624 YoY; EBIT was KSEK -11,547 versus -12,159.
Net loss was KSEK 11,560 versus KSEK 12,157; EPS was SEK -0.0607 versus -0.0658, and diluted EPS was SEK -0.0585.
Cash and cash equivalents were KSEK 16,407 at Sept. 30, 2026, versus KSEK 28,550 a year earlier.
Outlook and guidance
Near-term priorities include completing the Alpha1H Phase III study, pursuing market approval for bladder cancer and developing clinical programs for other indications; commercial progress remains contingent on trial outcomes and approval.
Plans include a separate study of Alpha1H in severe, therapy-resistant carcinoma in situ at the University of Iowa.
Anti-infective priorities include extending trials to more severe infections, advancing new compounds into clinical testing and continuing discussions with potential clinical partners.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hamlet BioPharma
- Alpha1H enters phase III as host-directed infection therapies advance.HAMLET
BioStock Life Science Summit 2026 - Alpha1H advances into Phase III as clinical programs expand across cancer, infection and pain.HAMLETInvestor update
- Phase III trial advances and BAMLET shows metabolic promise, with funding and partnerships in focus.HAMLETInvestor update
- Clinical progress and pipeline growth in oncology, anti-infectives, backed by strong R&D and financing.HAMLETQ4 25/26
- EMA approval and phase III readiness mark major clinical and scientific milestones.HAMLETInvestor update
- Advancing Alpha1H to Phase III, expanding partnerships, and maintaining robust R&D momentum.HAMLETQ3 25/26
- Advanced clinical pipeline and strong R&D drive progress toward pivotal Phase III studies.HAMLETQ2 25/26
- FDA backs pivotal trial for Alpha1H; leadership transitions and pipeline expansion underway.HAMLETLife Science Summit 2025
- Phase II successes, SEK 140M capital raised, and FDA support position Alpha1H for Phase III.HAMLETQ1 25/26
Next Hamlet BioPharma earnings date
Q2 26/2726 Feb, 2027
Hamlet BioPharma
Next Hamlet BioPharma earnings date
Q2 26/2726 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Hamlet Pharma AB, a pharmaceutical company, engages in the research and development of cancer drugs. The company's lead product candidate is a patented drug that combines the active ingredient Bisantrene-Guanidinylpenicillamine in a galenic form suitable for oral administration. Its BAR treatment is administered through small pills that slowly release the active ingredient into the upper part of the gastrointestinal tract. The company is headquartered in Malmö, Sweden.